托珠单抗在新型冠状病毒肺炎的应用研究探讨

The Clinical Application of Tocilizumab for the Treatment of COVID-19

2019年12月以来,新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)在武汉暴发并蔓延至全国,给整个社会带来巨大的挑战。部分COVID-19感染者早期发病并不十分凶险,但后期会突然加速进展,病人很快进入多脏器功能衰竭的状态,李兰娟院士等提出了"细胞因子风暴"概念。但目前并没有特效药物,认为IL-6是诱发细胞因子风暴的重要通路,本文结合相关文献的复习和分析,旨在综述IL-6受体阻断剂托珠单抗在新型冠状病毒肺炎危重患者使用的可行性。

The Coronavirus Disease 2019 (COVID-19) first detected in Wuhan,China,has spread rapidly since December 2019.The early onset of infected patients is not very dangerous,but maybe suffer a sudden acceleration to the state of multiple organ failure.Academician Li and other experts proposed the concept of "cytokine storm",and suggested that IL-6 maybe an important pathway to induce cytokine storm. This paper,combined with the review and analysis of relevant literature,aims to review the feasibility of the il-6 receptor blockers,tocilizumab,in the treatment of severe patients with novel coronavirus pneumonia.